HIV nanoparticle vaccine induces strong T-cell responses in early-phase clinical trial
An HIV nanoparticle vaccine has induced strong T-cell responses in a first-in-human clinical trial, marking a step toward the development of a product that protects against the virus. Read More
Clinical trial begins for universal flu vaccine candidate
Researchers at NIH’s National Institute of Allergy and Infectious Diseases (NIAIDs) have developed an experimental universal influenza vaccine. Read More
Biomarker predicts response to chemo-immunotherapy in lung cancer patients
Researchers have found a biomarker that provides an early indication of whether a patient is responding to chemo-immunotherapy. Read More
Novel glioblastoma treatment shows promising results
Toronto’s University Health Network (UHN) neurosurgeons have developed a novel glioblastoma therapy that combines the injection of an oncolytic virus directly into the tumor with intravenous immunotherapy. The results, published Monday in Nature Medicine, found that this combination therapy prolonged survival rates, providing clinical benefits to over half of the patients studied. Read More
Discovery of markers on long-lasting immune cells lights way to more durable vaccine responses
Researchers have identified surface markers on cells that continue producing antibodies for a long time, pointing to a way to improve the duration of response to vaccines. Read More
FDA approves first respiratory syncytial virus vaccine
The U.S. Food and Drug Administration (FDA) said Wednesday that it has approved the use of GlaxoSmithKline Biologicals’ Arexvy vaccine for respiratory syncytial virus (RSV). Read More
Specialized printer may help vaccines reach more people
Researchers have developed a specialized printer to generate vaccine-filled microneedle skin patches that can be stored long-term without refrigeration. Their research, published Monday in Nature Biotechnology, may eventually bring more vaccines to more people. Read More
Plasmid DNA vaccine protects mice from COVID-19 by triggering T-cell response
A plasmid DNA vaccine designed to trigger a T-cell response has protected most mice from a lethal dose of SARS-CoV-2, delivering preliminary evidence that the candidate may provide broader, more durable responses than existing COVID-19 shots. Read More
Testing vaccine candidates with lab-grown organoids
Researchers have developed a new testing platform that encapsulates B cells -- important immune system components -- into miniature lab-grown organoids. The results, published Wednesday in ACS Central Science, may hasten vaccine screening and significantly reduce the number of experimental animals used in the process, the researchers said. Read More
Driver of responses to checkpoint inhibitors suggests way to improve cancer therapy
Expansion of a diverse subset of T-cell clones influences how patients respond to immune checkpoint inhibitors (ICIs), suggesting it may be possible to predict who will benefit from the treatments. Read More
International Paper Physics Conference 2023 (IPPC2023)
May 31 - June 2
Guangzhou, Guangdong China
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter